Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint.

The HTS-based discovery and structure-guided optimization of a novel series of GKRP-selective GK-GKRP disrupters are revealed. Diarylmethanesulfonamide hit 6 (hGK-hGKRP IC50 = 1.2 μM) was optimized to lead compound 32 (AMG-0696; hGK-hGKRP IC50 = 0.0038 μM). A stabilizing interaction between a nitrogen atom lone pair and an aromatic sulfur system (nN → σ*S-X) in 32 was exploited to conformationally constrain a biaryl linkage and allow contact with key residues in GKRP. Lead compound 32 was shown to induce GK translocation from the nucleus to the cytoplasm in rats (IHC score = 0; 10 mg/kg po, 6 h) and blood glucose reduction in mice (POC = -45%; 100 mg/kg po, 3 h). X-ray analyses of 32 and several precursors bound to GKRP were also obtained. This novel disrupter of GK-GKRP binding enables further exploration of GKRP as a potential therapeutic target for type II diabetes and highlights the value of exploiting unconventional nonbonded interactions in drug design.

[1]  M. D. Hill,et al.  Applications of Fluorine in Medicinal Chemistry. , 2015, Journal of medicinal chemistry.

[2]  S. Chmait,et al.  Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis. , 2015, Journal of medicinal chemistry.

[3]  Marc Suhrcke,et al.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review , 2015, PharmacoEconomics.

[4]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[5]  J. Pfefferkorn,et al.  A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014 , 2014, Expert opinion on therapeutic patents.

[6]  S. Chmait,et al.  Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket. , 2014, Journal of medicinal chemistry.

[7]  R. Wahl,et al.  Discovery of Small-Molecule Glucokinase Regulatory Protein Modulators That Restore Glucokinase Activity , 2014, Journal of biomolecular screening.

[8]  R. Kunz,et al.  Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine series. , 2014, Journal of medicinal chemistry.

[9]  R. Wahl,et al.  Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept. , 2014, Journal of medicinal chemistry.

[10]  R. Kunz,et al.  Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles. , 2014, Journal of medicinal chemistry.

[11]  R. Wahl,et al.  Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors , 2013, Nature.

[12]  F. Matschinsky GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? , 2013, Trends in pharmacological sciences.

[13]  A. Gloyn,et al.  Small molecular glucokinase activators: has another new anti‐diabetic therapeutic lost favour? , 2013, British journal of pharmacology.

[14]  C. Fotsch,et al.  Mitigating heterocycle metabolism in drug discovery. , 2012, Journal of medicinal chemistry.

[15]  E. Verspohl,et al.  Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes , 2012, Pharmacological Reviews.

[16]  Yue Shentu,et al.  Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes , 2011, Diabetes Care.

[17]  Changhong Li,et al.  Glucokinase Activators for Diabetes Therapy , 2011, Diabetes Care.

[18]  A. Doweyko,et al.  Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[19]  J. Ellman,et al.  Synthesis and applications of tert-butanesulfinamide. , 2010, Chemical reviews.

[20]  D. Schmoll,et al.  Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein , 2008, Journal of Biological Chemistry.

[21]  Mark J. Kurth,et al.  Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. , 2008, Journal of medicinal chemistry.

[22]  L. Agius Glucokinase and molecular aspects of liver glycogen metabolism. , 2008, The Biochemical journal.

[23]  Mikael P. Johansson,et al.  Torsional Barriers and Equilibrium Angle of Biphenyl: Reconciling Theory with Experiment. , 2008, Journal of chemical theory and computation.

[24]  P. Stephens,et al.  The determination of the absolute configurations of chiral molecules using vibrational circular dichroism (VCD) spectroscopy. , 2008, Chirality.

[25]  B. Wang,et al.  Synthesis and Evaluation of Dual Wavelength Fluorescent Benzo[b]thiophene Boronic Acid Derivatives for Sugar Sensing , 2007, Chemical biology & drug design.

[26]  J. Grimsby,et al.  Targeting glucokinase activation for the treatment of type 2 diabetes--a status review. , 2005, Current opinion in drug discovery & development.

[27]  M. Schlosser,et al.  Creating Structural Manifolds from a Common Precursor: Basicity Gradient‐Driven Isomerization of Halopyridines , 2002 .

[28]  Clark R. Landis,et al.  NATURAL BOND ORBITALS AND EXTENSIONS OF LOCALIZED BONDING CONCEPTS , 2001 .

[29]  M. Botta,et al.  Chiral azole derivatives. 4. Enantiomers of bifonazole and related antifungal agents: synthesis, configuration assignment, and biological evaluation. , 2000, The Journal of organic chemistry.

[30]  B. Glaser,et al.  Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. , 1998, Diabetes.

[31]  E. Van Schaftingen,et al.  The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. , 1990, European journal of biochemistry.

[32]  F M Matschinsky,et al.  Glucokinase as Glucose Sensor and Metabolic Signal Generator in Pancreatic β-Cells and Hepatocytes , 1990, Diabetes.

[33]  M. Engelgau,et al.  Cost-of-Illness Studies in Diabetes Mellitus , 2012, PharmacoEconomics.